Gilead Sciences clears a fresh 12?month high, shares react to new FDA approval
27.06.2026 - 11:22:14 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 11:21.
Gilead Sciences (US3755581036) extends its recent run on NASDAQ with shares near a new 12?month high. The move follows fresh FDA approval for cancer drug Trodelvy in first-line triple?negative breast cancer and a consensus price target that remains clearly above the latest quote, according to Simply Wall St.
What the FDA approval changes
According to a detailed Simply Wall St note, the US Food and Drug Administration has approved Trodelvy as a first?line treatment for adult patients with advanced or metastatic triple?negative breast cancer. The label covers use as monotherapy and in combination with Merck's Keytruda for PD?L1 positive disease, adding a new front?line option in a difficult oncology segment.
Trodelvy is described as a first?in?class Trop?2 directed antibody?drug conjugate with overall survival data across multiple indications, which strengthens Gilead's oncology franchise beyond its traditional antiviral base. The approval broadens the commercial opportunity for the drug compared with prior later?line settings, giving Gilead an additional growth pillar alongside HIV treatments where peers such as AbbVie and Merck also compete.
Where the Gilead stock trades now
Marketbeat data show Gilead Sciences shares closed at 127.86 US dollars on NASDAQ on 26 June 2026, up 3.25 percent for the day. The same source highlights that this level marks a new 12?month high for the stock, signalling a marked change versus the muted momentum Simply Wall St noted over the past 30 days.
Simply Wall St reports that Gilead trades around 19 percent below a consensus price target of 157.57 US dollars, and roughly 51 percent below its own estimated fair value. That gap underlines that, despite the recent advance, many analysts still see upside potential compared with current NASDAQ prices, even as the stock has been volatile around prior Trodelvy news.
All news and analysis on the Gilead Sciences shares
Further updates on Gilead Sciences, including earnings, guidance and sector comparisons, can be found on the AD HOC NEWS topic page and the company's Investor Relations site.
The product behind the stock
Trodelvy, the antibody?drug conjugate at the center of the latest FDA decision, targets the transmembrane glycoprotein Trop?2 that is widely expressed in epithelial cancers. In breast cancer, the drug delivers a cytotoxic payload directly to tumour cells, aiming to improve overall survival compared with standard chemotherapy in advanced disease.
Where the shares trade today
Gilead Sciences shares (US3755581036) last traded at 127.86 US dollars on NASDAQ as of 2026-06-26, 15:59 Eastern Time.
Key data on the Gilead Sciences shares
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- WKN: 885823
- Ticker: GILD
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 15:59): 127.86 USD
- Market cap: around 160 billion USD (as of 2026-06-26, based on NASDAQ data)
- Sector / industry: Pharmaceuticals & Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Figures and dates are based on sources cited in the text and may change. Retail investors should consult multiple sources and, where appropriate, a financial adviser before making investment decisions.
